PBGENE-HBV is designed to potentially cure chronic hepatitis B by eliminating the root cause of the virus. The Food and Drug Administration (FDA) has granted Fast Track designation to PBGENE-HBV, an ...

Fran Gregory, PharmD, MBA, VP of emerging therapies at Cardinal Health, talks about the importance of market access strategies in the cell and gene therapy space.

People with diseases caused by rare mutations have fewer options and poorer prospects than other patients despite rapid ...

Found in the Finnish population, a rare variant of the TYROBP gene significantly increases the risk of Alzheimer's disease, a new study led by the University of Eastern Finland shows.

Emma Weston joined the clinical trial after running out of treatment options. For two years, she's been cancer free.

Announcing a new article publication for BIO Integration journal. Bladder cancer (BLCA) is one of the most common malignancies and the second most frequent urogenital tract tumor.